

# Huma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis

Jan 9, 2023

- *Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years*
- *Creates new and advanced digital solutions across all phases of clinical trials*
- *Accelerates patient recruitment and the development of new therapies through end-to-end digital-first research and care*

**LONDON, FRANKFURT, Jan. 9, 2023** Huma Therapeutics Limited (“Huma”), a leading global digital health company, today announced that it has acquired Alcedis GmbH (“Alcedis”), a market-leader for data driven clinical research and technology. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials.

Integrating Alcedis’ clinical and operational know-how with Huma’s digital expertise will make Huma the optimal healthtech provider, able to support the seamless integration of digital technology into clinical trials.

Headquartered in Germany, Alcedis has more than 25 years of clinical trial experience. Huma’s award-winning technologies have been deployed since 2011. Between them, Huma and Alcedis have managed nearly a thousand studies across a wide range of therapeutic areas, including rare diseases, oncology, immunology, cardiovascular, respiratory, neurodegenerative, musculoskeletal, dermatology and metabolic diseases, in over 60 countries involving more than 650,000 participants.